Chargement en cours...
Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine: Evidence From Randomized Controlled Trials
BACKGROUND: As one of the novel therapeutic drugs that targets Calcitonin gene-related peptide (CGRP), 75 mg rimegepant has been used for the acute management of migraine, which is one of the most common neurological diseases worldwide. Several clinical trials have been conducted to investigate the...
Enregistré dans:
| Publié dans: | Front Pharmacol |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Frontiers Media S.A.
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6992660/ https://ncbi.nlm.nih.gov/pubmed/32038251 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2019.01577 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|